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TCT-380
Hemodynamic Effects of a Catheter-Deployed Intra-Aortic Micro-Axial
Entrainment Pump in a Porcine Acute HF Model
Farshad Raissi Shabari1, Joggy George1, Michael Cuchiara2, Robert Langsner2,
Kyle Potts1, Jace Heuring2, Benjamin Hertzog2, Reynolds Delgado1
1Texas Heart Institute, Houston, TX, 2Procyrion Inc, Houston, TX
Background: This study examined the hemodynamic effects of Procyrion’s
catheter-deployed, partial circulatory support device in a porcine acute heart
failure (HF) model. Long-term circulatory support (LTCS) is currently limited to
large devices with invasive and risky surgical implantations and therefore is
restricted to NYHA Class IV HF patients. In contrast, Procyrion’s device is an
intra-aortic micro-axial entrainment pump implanted with cath-lab techniques and
is intended for LTCS in earlier stage HF patients.
Methods: The pump was deployed in the thoracic aorta and anchored using self-
expanding struts. Acute cardiac dysfunction was induced via continuous esmolol infusion
until cardiac contractility was 50% of the pre-esmolol baseline. Hemodynamic effects
were recorded using a pressure-volume catheter (left ventricle), a flow probe (renal artery)
and pressure catheters (aorta and renal artery). Effects were evaluated from changes in
hemodynamic parameters between baseline (device off) and device on.
Results: The intra-aortic pump increased cardiac output, stroke volume, ejection fraction,
and renal flow and pressure while decreasing cardiac stroke work, afterload and
end-diastolic pressure.
Conclusions: This study demonstrates that the catheter based intra-aortic fluid entrain-
ment pump improves porcine acute HF hemodynamics. Additionally, improved renal
perfusion may enhance HF treatment and disrupt cardiorenal syndrome. These results
suggest the intra-aortic pump has the potential to improve HF outcomes and quality-of-life
by resting the heart, promoting reverse remodeling and augmenting end-organ perfusion.
TCT-381
First Report of Acute and Short-term Outcomes from a Confirmatory (Cohort
B) Study of Percutaneous Ventricular Restoration (PVR) therapy using the
Parachute Device in Patients with Ischemic Dilated Heart Failure
Martyn Thomas1, Marco Costa2, Christoph Nienaber3, Hüseyin Ince3,
Andrejs Erglis4, William Abraham5
1St Thomas’ Hospital, London, United Kingdom, 2Case Western Reserve
University, Cleveland, USA, 3University of Rostock, Rostock, Germany, 4Pauls
Stradins Clinical University Hospital, Riga, Latvia, 5Ohio State Univeristy,
Columbus, USA
Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction
(AWMI) leads to increased LV volumes, myocardial stress, and ultimately heart failure
(HF). Treatment options are limited for these high-risk HF patients. Two prior first-in-man
studies of PVR using the Parachute TM device support the safety and efficacy of this
approach. An ongoing study (Cohort B) was designed to confirm these observations and
to evaluate an extended range of 8 device sizes, prior to launching a U.S. pivotal
randomized controlled trial.
Methods: Aims: To confirm the acute safety and acute and long-term efficacy of PVR
using an expanded range of Parachute TM device sizes in patients with ischemic HF with
prior AWMI. Methods: Up to 60 patients with NYHA class II-IV HF secondary to
AWMI, with akinetic or dyskinetic wall motion abnormality, LV ejection fraction 40%,
and have been fully revascularized are being enrolled into this non-randomized trial at 15
European sites. Major endpoints were death and repeat hospitalization.
Results: As of June 1, 2012, 38 patients were treated. Parachute was implanted
successfully in all patients. There were no procedural (n38) or 30-day (n34) stroke or
death observed. Enrollment and 6 month FU on 30 patients will be completed by October
1, 2012. Results will be available for presentation.
Conclusions: This ongoing trial of PVR using an expanded range of Parachute TM
device sizes in patients with ischemic HF and prior AWMI is anticipated to confirm the
safety and efficacy of this approach to treating HF, thus supporting the conduct of a
subsequent RCT.
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Percutaneous and Surgical Circulatory Support for Medically Refractory
Right Ventricular Failure with a Centrifugal-Flow Pump
Navin Kapur1, Vikram Paruchuri1, Michael Kiernan1, Duc Pham1,
Anjan Chakrabarti2, Duane Pinto3, Daniel Steinberg4, Nicole Orr5, John Finley6,
Michael Templehoff7, Nima Aghili8, Samer Najjar9, James Mudd10,
David DeNofrio1
1Tufts Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center,
Boston, MA, 3Beth Israel Deaconess Medical Center, Boston, USA, 4Medical
University of South Carolina, Charleston, SC, 5St. Francis Hospital, Roslyn, NY,
6Thomas Jefferson University Hospital, Philadelphia, PA, 7Northwestern
University, Chicago, IL, 8Washington Hospital Center, Washington, DC,
9Washington Hospital Center, Washington , DC, 10Oregon Health Sciences
University, Portland, OR
Background: Medically refractory right ventricular failure (MR-RVF) is associated with
high in-hospital mortality and is managed with intra-aortic balloon counterpulsation, right
ventricular assist devices, atrial septostomy, or extracorporeal membrane oxygenation.
Limited data exist supporting use of the TandemHeart right ventricular support device
(TH-RVSD;CardiacAssist Inc) for MR-RVF.The goal of this study was to explore the
clinical utility of the TH-RVSD in MR-RVF.
Methods: We explored the clinical efficacy and safety of the TH-RVSD in 46 patients
with MR-RVF. All patient data was retrospectively collected in the TandemHeart RIght
VEntricular support (THRIVE) registry comprising 8 tertiary care hospitals in the United
States.
Results: MR-RVF was due to chronic heart failure in 7%(n3), myocarditis in
7%(n3), post-valve surgery in 32%(n15), post-orthotopic heart transplant in
11%(n5), post-left ventricular assist device surgery in 11%(n5), post-coronary bypass
grafting in 7%(n3), and acute myocardial infarction (AMI) in 26%(n12) of subjects.
Concomitant placement of a left ventricular assist device due to biventricular failure
occurred in 24%(n11) of subjects. Percutaneous(48%;n22) and surgical(52%;n24)
cannulation approaches were studied. No intra-procedural mortality was observed. Two
vascular complications were noted. Thrombolysis in Myocardial Infarction (TIMI) major
bleeding occurred in 42% of patients. Time from admission to TH-RVSD implantation
was 5.7	8.5 days with an average of 6769 789 rotations per minute, providing 4.2	1.3
L/min of flow. Mean duration of TH-RVSD use was 5.4	5.1 days. Compared to
pre-procedural values, mean arterial pressure (67	12vs74	14,p0.05), right atrial
pressure (21	9vs16	6,p0.05), pulmonary artery systolic pressure
(43	15vs33	15,p0.01), cardiac index (1.7	0.7vs2.5	1.1,p0.05), and mixed ve-
nous oxygen saturation (52	15vs.65	10,p0.01) improved within 48 hours of TH-
RVSD implantation. Total in-hospital mortality was 52.5%(n21) and was lowest
amongst acute IWMI patients (33%;n3).
Conclusions: Use of the TH-RVSD for MR-RVF is feasible and associated with
improved hemodynamics. Algorithms promoting mechanical RVSD use in MR-RVF
warrant further investigation.
TCT-383
Transcutaneous-Powered Electrohydraulic Counterpulsation System For
Ambulatory Non-Obligatory Chronic Heart Failure Treatment
William Cohn1, Mark Slaughter2, Rodney Parkin3, Dan Lafontaine4,
William Peters3
1Texas Heart Institute, Houston, TX, 2University of Louisville, Louisville, KY,
3Sunshine Heart, Inc., Eden Prairie, MN, 4Sunshine Heart, Inc, Eden Prairie, MN
Background: A non-blood contacting, non-obligatory extra-ascending aortic counter-
pulsation Cuff and sense lead coupled to a percutaneous pneumatic drive system (C-Pulse;
Sunshine Heart, Inc, Eden Prairie MN) has been used in investigational clinical studies in
patients with moderate to severe heart failure. A fully implanted electrohydraulic
counterpulsation system utilizing the same Cuff design and incorporating both transcuta-
neous energy transfer (TET) and a defibrillator has been developed.
Methods: Following engineering analysis and cadaver fit studies, two electro-
hydraulic pumps were constructed; single liquid and dual liquid designs, both
using the same motor mechanism. The pump sits in the right pleural space and is
coupled to an extra-aortic inflatable Cuff via a short, wide lumen. The internal
controller has an attached internal TET coil, and also receives an IS-1 cable from
an implantable CRT-D pulse generator. The CRT-D and internal controller can be
programmed remotely. Integrated system testing was completed on the bench and
verified in an acute preclinical study.
Results: Bench testing demonstrated the systems provided 1:1 counterpulsation at
nominal physiological conditions (HR 80 bpm, MAP 90 mmHg, Cuff displace-
ment 14 cc per beat). These results correlated with preclinical testing in a calf
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model; (HR 80-100 bpm paced and unpaced, MAP 70-100 mmHg, Cuff displace-
ment 14 cc per beat). The counterpulsation effect was optimized in 1:2 mode and
measurements made in 1:1 mode (Fig 1). The measured motor power was
2.7-3.9W. There was no significant temperature gradient measured at either the
pump or internal coil versus surrounding tissues.
Conclusions: A fully implanted counterpulsation system is technically feasible, with low
power usage and no requirement for an implanted battery. Furthermore, the system can be
coupled with brady-tachy pacemaker technology, allowing for a novel, synergistic
electrical–mechanical cardiac assist system.
TCT-384
The Coronary Sinus Reducer – a Device Based Therapy for Refractory
Angina; Interim Safety Results of the ongoing COSIRA clinical Trial and
efficacy results of the CS Reducer Registry
Shmuel Banai1, Marc Jolicoeur2, Jean-François Tanguay3, Elazer Edelman4,
Stefan Verheye5
1The Tel Aviv Medical Center, Israel, Tel Aviv, Israel, 2Montreal Heart Institute,
Montreal, Quebec, 3University of Montreal, Montreal, Canada, 4Harvard-MIT
Biomedical Engineering Center, Cambridge, Massachusetts, 5Antwerp
Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp, Belgium
Background: Refractory angina pectoris despite medical therapy in patients who are not
amenable for revascularization procedures is a relatively common clinical problem.The
quality of life of these no-option patients with so-called therapy-refractory angina pectoris
is poor as these patients need to change their life style according to their level of pain and
anxiety. A potential solution to alleviate the problem of reversible subendocardial
ischemia is to redistribute intramyocardial blood flow from the less ischemic subepicardial
myocardium towards the under-perfused and ischemic subendocardial myocardium.This
can be achieved by implanting a Reducer in the coronary sinus (CS). The hourglass-
shaped stent-like device creates over time a narrowing thereby increasing the venous
pressure and thus allowing intramyocardial flow reversal relieving the symptoms of pain
due to ischemia.
Methods: The COSIRA (Coronary Sinus Reducer for Treatment of Refractory
Angina) is a prospective, multicenter, randomized, double-blind, sham-controlled
clinical trial of the safety and effectiveness of the CS Reducer. The trial is
ongoing, and more than 80 patients have been enrolled in Europe and Canada. It
consists of baseline assessments, implantation of the Reducer in the study group,
and assessments of both study and sham-control groups at hospital discharge, 30
days, 3 months and 6 months.
Results: The primary endpoint of this trial is a decrease in two or more CCS grades from
baseline to six-month post-procedural evaluation in Reducer and control groups. A
parallel CS Reducer registry is ongoing, in which patients with refractory angina are
treated with CS Reducer implantation on a compassionate use basis.
Conclusions: The 6 months safety results of the COSIRA trial as well as the safety and
efficacy results of the Reducer registry will be presented at TCT 2012.
TCT-385
Comparative Economic Outcomes in Cardiogenic Shock Patients Managed
with the Minimally Invasive Impella or Extracorporeal Life Support
Anson Cheung1, Matthew Danter2, David Gregory3
1St Pauls Hospital, Vancouver, British Columbia, 2University of British Columbia,
Vancouver, British Columbia, 3Presscott Associates, Ltd., Avon, CT
Background: Despite advances in cardiovascular medicine, acute decompensated heart
failure and post-cardiotomy shock is associated with alarmingly high mortality rates. Until
recently, temporary mechanical support has included the intra-aortic balloon pump
(IABP) and extracorporeal membrane oxygenation (ECMO). The Impella 5.0 device is a
minimally invasive microaxial pump, designed to provide superior clinical support for
these failing patients in a cost-effective manner.
Methods: This retrospective study compares the economic outcomes of patients
receiving circulatory support with either ECMO or the Impella LP5.0, and builds on our
previously published clinical study on these patients. Hospital resource data was collected
for both study arms, to include blood product costs, perfusion costs, ICU costs, and length
of stay (LOS) for 29 Impella and 31 ECMO patients.
Results: In a well-matched clinical sample of Impella and ECMO patients, total
mean costs to the hospital were reduced by 12% for the initial index stay of
Impella patients. This reduction was driven by a significant 61% reduction in
blood product costs (p0.001), confirming the minimally invasive design of the
Impella cardiac assist device. Related, there was a 100% reduction in perfusion
costs, as Impella patients do not require perfusion assistance. Additionally, ICU
costs were reduced in the Impella arm by 25%, driven primarily by 4.8 fewer ICU
days of stay for Impella patients.
Conclusions: For patients requiring emergent hemodynamic support, the Impella cardiac
assist device appears to offer a less invasive alternative that not only improves outcomes
but also reduces costs over ECMO therapy. These findings have significant operational
implications for providers, both in the single-payer Canadian system, as well as in the U.S.
healthcare system as providers embrace recent health reforms.
TCT-386
Predictors of In-Hospital Mortality in Patients Undergoing Pericardiocentesis
in United States
Paul Hermany1, Chad Zack1, Vladimir Lakhter1, Alfred Bove1, Riyaz Bashir1
1Temple University School of Medicine, Philadelphia, PA
Background: The national rates of in-hospital mortality in patients undergoing pericar-
diocentesis in the United States are not known.
Methods: The Nationwide Inpatient Sample (NIS) database was used to identify patients
who underwent pericardiocentesis from 2005 to 2009. We used risk-adjusted logistic
regression to analyze the predictors of in-hospital mortality.
Results: A total of 49,850 patients underwent pericardiocentesis during the five-year
study period. The in-hospital mortality was noted to be 15.5%. The following factors were
identified as significant independent predictors of in-hospital death: shock (OR 4.65; 95%
CI 3.99-5.41), renal failure (OR 1.24; 95% CI 1.06-1.45), peripheral vascular disease (OR
1.32; 95% CI 1.04-1.67), neurologic disorders (OR 1.74; 95% CI 1.38-2.20), metastatic
cancer (OR 1.74; 95% CI 1.45-2.09), coagulopathy (OR 1.91; 95% CI 1.60-2.26),
electrolyte abnormalities (OR 1.55; 95% CI 1.38-1.74) and liver disease (OR 1.58; 95%
CI 1.20-2.09).
Conclusions: In this observational study, we found that the in-hospital mortality after
pericardiocentesis continues to be high in United States. Shock, renal failure, peripheral
vascular disease, neurologic disorders, metastatic cancer, coagulopathy, electrolyte
abnormalities, and liver disease were significantly associated with an increased risk of
in-hospital mortality.
TCT-387
Short- and Long-term Outcomes of Coronary Revascularization in Patients
with Severe Left Ventricular Dilatation
Wang Xiao1, Nie Shaoping1, Liu Xiaohui1, Kang Junping1, Lv Qiang1, Du Xin1,
Ma Changsheng1
1Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Background: Patients with coronary artery disease accompanied by severe left ventric-
ular dilatation (LVD) are at higher risk for heart failure and death. However, their clinical
and angiographic profiles, short- and long-term outcomes after revascularization are
unknown.
Methods: A total of 4,283 patients (median age 60.0 years; 77.4% male) with coronary
artery disease undergoing percutaneous or surgical revascularization in our center from
July, 2003 to September, 2005 were stratified according to end-diastolic dimension
(EDD). Patients with severe LVD (EDD70 mm), mild/moderate LVD (EDD 52.7mm
to 70.0mm in males, EDD 48.3mm to 70.0mm in females), and no LVD (EDD52.7mm
in males, EDD48.3mm in females) was compared for outcome analysis.
Results: Patients with severe LVD had more complex lesions (eg. chronic total
occlusions, multi-vessel disease) with more prior myocardial infarction, valvular impair-
ments and renal dysfunction (all p0.001). Patients successfully discharged were
followed up for a median of 548 (455-669) days. Severe LVD was significantly associated
with increased in-hospital mortality (5.4% vs 1.6% vs 1.0%, p0.001) and composite
ischemia (all-cause mortality, myocardial infarction, stroke and repeat revascularization)
(6.9 % vs 2.5% vs 2.1%, p0.001) compared with mild/moderate LVD and no LVD
groups. By multivariable analysis, severe LVD was a significant independent predictor of
in-hospital (HR 1.858, 95% CI 1.323-2.611, p0.001) and follow-up mortality (HR
1.460, 95% CI 1.037-2.054, p0.030) after revascularization.
Conclusions: Patients with severe LVD have more co-morbidities and complex coronary
lesions. Severe LVD in patients undergoing coronary revascularization was an indepen-
dent predictor of early and late mortality and adverse ischemic outcomes.
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